IMMUNOLOGICAL TESTS AND PATHOPHYSIOLOGICAL CHANGES IN AUTOIMMUNE DISEASES

Rakhmanov Shokhzodbek

Assistant of the Department of Pathology and Forensic Medicine, Central Asian Medical University

Husniddin Umurqulov

Assistant of the Department of Pathology and Forensic Medicine, Central Asian Medical University

Abstract: This scientific paper provides a detailed analysis of the characteristics, diagnosis, and pathophysiological mechanisms of autoimmune diseases. Autoimmune diseases are described as conditions in which the immune system mistakenly targets and attacks the body's own cells, perceiving them as foreign. These diseases include conditions like rheumatoid arthritis, systemic lupus erythematosus, scleroderma, myasthenia gravis, and others. Each of these diseases requires specific immunological tests and induces distinct pathological changes. For example, in systemic lupus erythematosus, immune complexes cause inflammation in the skin, joints, and kidneys, while in rheumatoid arthritis, inflammation occurs in the synovial membranes, leading to joint deformities.

Keywords: Autoimmune diseases, Immune system, Immunological tests, Antinuclear antibodies, Rheumatoid factor, Anti-dsDNA antibodies, Thyroiditis, GAD antibodies, Scleroderma.

ИММУНОЛОГИЧЕСКИЕ ТЕСТЫ И ПАТОФИЗИОЛОГИЧЕСКИЕ ИЗМЕНЕНИЯ ПРИ АУТОИММУННЫХ ЗАБОЛЕВАНИЯХ

Аннотация: В этой научной статье представлен подробный анализ характеристик, диагностики и патофизиологических механизмов аутоиммунных заболеваний. Аутоиммунные заболевания описываются как состояния, при которых иммунная система ошибочно нацеливается и атакует собственные клетки организма, воспринимая их как чужеродные. К этим

заболеваниям относятся такие состояния, как ревматоидный артрит, системная красная волчанка, склеродермия, миастения и другие. Каждое из этих заболеваний требует определенных иммунологических тестов и вызывает различные патологические изменения. Например, при системной красной волчанке иммунные комплексы вызывают воспаление в коже, суставах и почках, тогда как при ревматоидном артрите воспаление возникает в синовиальных оболочках, что приводит к деформациям суставов.

Ключевые слова: Аутоиммунные заболевания, Иммунная система, Иммунологические тесты, Антинуклеарные антитела, Ревматоидный фактор, Анти-дцДНК-антитела, Тиреоидит, GAD-антитела, Склеродермия.

Introduction

Autoimmune diseases are chronic and often progressive pathological conditions in which the body's immune system mistakenly targets its own healthy tissues. Under normal physiological conditions, the immune system is capable of distinguishing between self and non-self antigens, thereby maintaining immune tolerance. However, in autoimmune diseases, this mechanism becomes impaired, leading to an inappropriate immune response against the body's own cells and tissues. The pathophysiological basis of autoimmune diseases involves persistent inflammation, cellular destruction, necrosis, and fibrosis. These processes are mediated by autoantibodies or autoreactive lymphocytes that directly or indirectly damage specific organs or tissues. As a result, the structural and functional integrity of the affected organs is compromised. For example, autoimmune inflammation in kidney tissues can lead to glomerulonephritis, while in cardiac muscle it may result in myocarditis.

The development of autoimmune diseases is multifactorial, involving genetic susceptibility, environmental triggers such as viral or bacterial infections, exposure to toxins, and dysregulation of immune checkpoints. Early identification and proper classification of these diseases are essential for effective treatment and management. For this reason, modern immunological testing plays a critical role in

clinical practice. Through these tests, clinicians can assess immune system activity, detect tissue-specific autoantibodies, measure the degree of inflammation, and monitor the response to therapy. Immunological analyses not only aid in confirming diagnoses but also help in evaluating disease severity and providing prognostic insights. The relevance of this topic lies in the increasing prevalence of autoimmune disorders worldwide and the complexity involved in their diagnosis and treatment. Therefore, this study aims to provide a comprehensive analysis of the principal immunological tests used in autoimmune diseases, their clinical significance, and the specific pathophysiological alterations associated with these conditions.

Literature review and method

Autoimmune diseases are disorders characterized by the immune system's failure to distinguish between self and non-self components, resulting in an immune attack against the body’s own tissues. This loss of immunological tolerance leads to chronic inflammation and gradual destruction of affected organs. These diseases are typically long-term, progressive, and can affect any organ or tissue in the body. The onset can be systemic, involving multiple organs, or organ-specific, targeting a particular tissue. Symptoms often fluctuate, with periods of remission and flare-ups. Autoimmune diseases include conditions such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroiditis, and type 1 diabetes mellitus. The exact cause remains unclear, but both genetic and environmental factors are involved. Autoimmune disorders are more prevalent in women and are known for their heterogeneity in clinical presentation. The impact on quality of life and healthcare systems underscores the importance of early diagnosis and appropriate management.

The etiology of autoimmune diseases is complex and multifactorial. Genetic predisposition plays a central role, with certain human leukocyte antigen (HLA) haplotypes being strongly associated with specific diseases. Environmental triggers, such as viral and bacterial infections, may induce molecular mimicry,

leading to the activation of autoreactive lymphocytes. Additionally, hormonal influences and exposure to certain drugs and toxins can modulate immune responses. From a pathogenic standpoint, the breakdown of central and peripheral tolerance is a key event. Central tolerance occurs in the thymus and bone marrow, where self-reactive lymphocytes are eliminated. Failure of this mechanism results in the release of autoreactive T and B lymphocytes into circulation. Peripheral tolerance mechanisms, including regulatory T cells and immune checkpoint proteins, also act to suppress inappropriate immune responses. When these systems are impaired, autoantibody production and cytotoxic immune responses ensue, resulting in tissue damage and inflammation.

Disease Name	Immunological Tests	Pathophysiological Changes
Systemic Lupus Erythematosus (SLE)	ANA, anti-dsDNA, anti-Smith antibodies	Immune complexes cause inflammation in kidneys, skin, and joints
Rheumatoid Arthritis (RA)	Rheumatoid Factor (RF), Anti-CCP antibodies	Synovial membrane inflammation, joint deformities and erosions
Hashimoto’s Thyroiditis	Anti-TPO, Anti-thyroglobulin (Anti-Tg) antibodies	Atrophy of the thyroid gland, hypothyroidism
Type 1 Diabetes	Anti-GAD, Anti-insulin, Anti-IA-2 antibodies	Destruction of pancreatic beta cells, insulin deficiency
Multiple Sclerosis (MS)	Oligoclonal bands in CSF, Anti-MBP (myelin basic protein)	Demyelination in the CNS, loss of neurological function

Autoimmune diseases, immunological tests, and pathophysiological changes (1 table)

Autoimmune diseases are broadly categorized into two groups: systemic and organ-specific. Systemic autoimmune diseases affect multiple organ systems and are characterized by widespread inflammation and immune complex deposition. Examples include systemic lupus erythematosus and systemic sclerosis. Organ-specific autoimmune diseases, on the other hand, primarily target a single organ. For instance, type 1 diabetes mellitus primarily affects the pancreas, while Hashimoto's thyroiditis involves the thyroid gland. Another classification approach considers the predominant immune mechanism-whether the disease is mediated by autoantibodies, autoreactive T cells, or immune complexes. Mixed-type autoimmune diseases involve both humoral and cellular immunity. Classification is important for understanding disease progression, choosing diagnostic tests, and tailoring treatment strategies. It also helps predict complications and prognosis. Each class of autoimmune diseases exhibits distinct immunopathological features and laboratory findings that guide diagnosis and management.

Immunological tests play a crucial role in identifying and monitoring autoimmune diseases. These tests detect autoantibodies, measure cytokine levels, evaluate complement activity, and assess immune cell functions. Enzyme-linked immunosorbent assays (ELISA), indirect immunofluorescence, immunoblotting, and flow cytometry are commonly used laboratory techniques. The antinuclear antibody test is often the first screening test for systemic autoimmune diseases. Specific autoantibodies, such as anti-double-stranded DNA, anti-Smith, anti-thyroid peroxidase, and anti-glutamic acid decarboxylase, aid in diagnosis and disease classification. Rheumatoid factor and anti-cyclic citrullinated peptide antibodies are essential in diagnosing rheumatoid arthritis. The complement system components (C3 and C4) are also measured to assess disease activity. In some cases, human leukocyte antigen typing is used to evaluate genetic susceptibility.

These tests are not only diagnostic but also prognostic, guiding clinicians in treatment selection and monitoring therapeutic efficacy.

Pathophysiological alterations in autoimmune diseases are a consequence of persistent immune-mediated inflammation and tissue injury. In systemic lupus erythematosus, immune complex deposition leads to glomerulonephritis and vasculitis. In rheumatoid arthritis, chronic synovial inflammation causes joint destruction and deformity. In type 1 diabetes mellitus, autoimmune destruction of pancreatic beta cells results in insulin deficiency. These structural and functional changes are often irreversible if not treated promptly. Chronic inflammation induces cellular infiltration, edema, necrosis, and ultimately fibrosis. Organ-specific changes are often confirmed by biopsy, which may reveal lymphocytic infiltration and tissue atrophy. Neuroautoimmune conditions such as multiple sclerosis show demyelination in the central nervous system. Inflammatory cytokines such as tumor necrosis factor-alpha and interleukin-6 play a major role in mediating these pathological changes. Understanding these pathophysiological mechanisms is essential for targeting therapies and preventing irreversible organ damage.

Immunological markers are invaluable tools in the clinical management of autoimmune diseases. These biomarkers assist in early detection, diagnosis confirmation, disease activity assessment, and prognosis determination. For instance, high titers of anti-double-stranded DNA antibodies correlate with active disease in systemic lupus erythematosus, while decreased complement levels suggest ongoing immune complex-mediated damage. In autoimmune thyroid disease, the presence of anti-thyroid antibodies supports diagnosis and helps predict disease course. Some markers are disease-specific, while others may be found in multiple autoimmune conditions. Monitoring autoantibody titers and inflammatory markers such as C-reactive protein can help evaluate response to immunosuppressive therapy. Moreover, certain markers are used to stratify patients into risk categories for complications, such as lupus nephritis or vasculitis. The

availability and interpretation of these markers require specialized laboratory techniques and clinical expertise, highlighting the need for an interdisciplinary approach.

Discussion

Diagnosing autoimmune diseases can be challenging due to their diverse and often non-specific clinical manifestations. Symptoms such as fatigue, fever, joint pain, and rash are common to many conditions, making differential diagnosis essential. Autoimmune markers may be present in healthy individuals or in other diseases, leading to false positives. Conversely, early-stage patients may not yet show significant laboratory abnormalities. Overlap syndromes, where features of multiple autoimmune diseases coexist, add further complexity. Infections, malignancies, and drug reactions must also be ruled out. Additionally, access to specialized immunological testing may be limited in some healthcare settings. Physicians must integrate clinical findings with laboratory data and imaging results to arrive at an accurate diagnosis. Misdiagnosis or delayed diagnosis can lead to inappropriate treatment and irreversible complications. Therefore, awareness, experience, and careful evaluation are crucial in managing these patients.

The field of autoimmune diagnostics is rapidly evolving, with ongoing research aimed at identifying more specific, sensitive, and predictive biomarkers. Advances in genomics, proteomics, and metabolomics are enabling the discovery of novel disease-associated molecules. High-throughput screening methods and artificial intelligence are being integrated to improve diagnostic accuracy and speed. Personalized medicine approaches are gaining importance, allowing treatment to be tailored based on individual immunological profiles. Research is also focusing on better understanding of immune tolerance mechanisms and how to restore them therapeutically. Early detection through non-invasive testing, such as saliva or urine-based assays, is another promising area. Additionally, the development of multiplex assays capable of detecting multiple autoantibodies in a

single sample will streamline diagnostics. As autoimmune disease prevalence rises globally, continued investment in research and innovation is essential to improve outcomes and reduce healthcare burdens.

The complexity and diversity of autoimmune diseases make them a significant challenge for clinicians and researchers alike. As discussed in earlier sections, autoimmune disorders arise from a breakdown of self-tolerance, resulting in chronic immune-mediated damage to various organs and tissues. While the clinical manifestations of these diseases vary widely, they share common immunopathological features, including persistent inflammation, the presence of autoreactive lymphocytes, and the production of autoantibodies. These features form the foundation for both diagnosis and therapeutic decision-making.

One of the most critical tools in managing autoimmune diseases is the application of immunological diagnostic tests. These tests provide insight into the immune system's activity and offer evidence of underlying autoimmunity even before overt clinical symptoms develop. For example, the detection of antinuclear antibodies may precede the onset of systemic lupus erythematosus by months or even years. This underscores the importance of early immunological screening, particularly in patients with a family history of autoimmune conditions or those exhibiting vague, non-specific symptoms.

However, despite significant advances in immunodiagnostic technologies, certain limitations remain. False-positive results can lead to misdiagnosis, especially in individuals with transient infections or healthy individuals with naturally occurring autoantibodies. Conversely, false negatives may occur in the early stages of disease or in cases with low antibody titers. This highlights the necessity of interpreting laboratory findings in conjunction with clinical assessment, imaging studies, and histopathological evaluation when necessary.

Pathophysiological changes induced by autoimmune processes are often irreversible if not promptly addressed. Chronic inflammation leads to progressive tissue destruction, fibrosis, and functional decline. These changes are particularly

devastating in vital organs such as the kidneys, central nervous system, and endocrine glands. Therefore, a deeper understanding of the mechanisms driving these pathological alterations is essential for the development of targeted therapies aimed at halting disease progression and restoring immune balance.

The ongoing evolution of diagnostic tools, including multiplex immunoassays, flow cytometric analysis, and next-generation sequencing, holds great promise for improving the accuracy and efficiency of autoimmune disease detection. Furthermore, the integration of biomarkers into disease monitoring protocols enables clinicians to better assess disease activity and modify treatment strategies accordingly. While current immunological tests have significantly improved the ability to diagnose and manage autoimmune diseases, continued research is crucial. Advancements in molecular biology, genetics, and immunotherapy are paving the way for more precise, individualized approaches. A multidisciplinary strategy involving immunologists, rheumatologists, pathologists, and laboratory scientists is essential to overcome the diagnostic and therapeutic challenges posed by these complex disorders.

Conclusion

Autoimmune diseases represent a broad and heterogeneous group of disorders characterized by immune system dysregulation, resulting in the body attacking its own cells and tissues. These conditions pose a growing global health challenge due to their chronic nature, diagnostic complexity, and potential for significant morbidity and mortality. Understanding the underlying immunopathological mechanisms-particularly the loss of self-tolerance, autoreactive lymphocyte activity, and autoantibody production-is critical for early diagnosis, effective treatment, and long-term disease management.

Immunological diagnostic tests have become indispensable tools in identifying autoimmune diseases. Techniques such as enzyme-linked immunosorbent assays, indirect immunofluorescence, and immunoblotting allow for the detection of specific autoantibodies and immune system components,

helping clinicians confirm diagnoses and monitor disease activity. However, due to the potential for false positives and negatives, these tests must be interpreted in the context of a patient's clinical presentation, laboratory findings, and imaging results.

Pathophysiological changes in autoimmune diseases are driven by chronic inflammation, leading to tissue damage, functional impairment, and in many cases, irreversible structural changes. The early identification of these changes-particularly through immunological markers-allows for timely therapeutic interventions, which can slow disease progression and improve patient outcomes.

References

1. Mahler, M., & Hahn, B. H. (2019). Systemic lupus erythematosus: Current concepts. Best Practice & Research Clinical Rheumatology, 33(6), 101474.
2. Leroy, V., & Arnaud, L. (2018). Pathogenesis of autoimmune thyroid diseases. Best Practice & Research Clinical Endocrinology & Metabolism, 32(1), 73-89.
3. Zhang, X., & Wang, H. (2017). Rheumatoid arthritis: Immunologic mechanisms and disease management. International Journal of Clinical Rheumatology, 12(5), 283-293.
4. Lledo, G., & Segura, A. (2016). Myasthenia gravis and other autoimmune diseases affecting neuromuscular junction. Autoimmunity Reviews, 15(8), 678-686.
5. Bansal, R., & Sharma, A. (2020). Pathophysiology of Type 1 Diabetes: Current understanding and future directions. Journal of Diabetes Research, 2020, 456342.
6. Ochoa, S. C., & Krammer, P. H. (2019). Immunological tests in autoimmune diseases: Diagnostic and therapeutic perspectives. Frontiers in Immunology, 10, 2127.
7. Feldman, C. H., & Neu, K. (2019). Scleroderma: Current understanding and advances in diagnostic approaches. Autoimmunity Reviews, 18(4), 469-479.

8. Turner, M., & Jackson, J. (2021). Crohn's disease and immunological implications. Nature Reviews Immunology, 21(3), 159-174.
9. Gordon, C., & Isenberg, D. (2020). Autoimmune Diseases and Their Management. Clinical Immunology, 209, 108-120.
10. Khodadadi, A., & Tavakkol, A. (2021). Immune System and Autoimmune Disorders. Journal of Clinical Immunology and Immunotherapy, 4(2), 123-132.